Why NPN Applications Get Rejected in Canada — and How to Prevent It

Most NPN applications that fail do so before the reviewer even reads the evidence.

That’s a hard reality for manufacturers who’ve spent months — and sometimes hundreds of thousands of dollars — developing a product, only to receive a Notice of Deficiency or outright rejection from Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) months after submission. The evidence might be solid. The product might be genuinely safe and effective. But if the dossier is structurally flawed — missing attestations, mismatched labelling, or an incorrectly classified evidence class — it won’t matter how strong your underlying science is.

Canada’s Natural Health Products Regulations (SOR/2003-196), in force since January 1, 2004, establish a licensing framework that’s considerably more prescriptive than many applicants anticipate. More than 120,000 products currently hold an active NPN or DIN-HM in Canada. That pool represents decades of accumulated submissions — many of which went through at least one round of deficiencies before reaching approval.

Here’s what we see go wrong most consistently, and how to address it before your dossier ever reaches a reviewer.

What the Natural Health Products Regulations Actually Require

Before getting into common failure points, it’s worth grounding the discussion in what Health Canada is actually evaluating. Under Section 5 of the NHPR, a product licence application must include:

• The product name (brand name, and the proper name of each medicinal ingredient)
• Quantitative composition of all medicinal and non-medicinal ingredients
• Evidence of safety and efficacy appropriate to the evidence class claimed
• A proposed label that meets Schedule 1 requirements
• Applicable attestations for traditional use claims
• Recommended conditions of use — dosage form, route of administration, dose, duration, and all applicable risk information

The NNHPD reviews applications against three broad evidence classes. Class I covers attestation-based traditional use, where a product can demonstrate 50+ years of traditional use with at least 15 of those years in the reference culture. Class II applies to products with published literature supporting safety and efficacy. Class III requires clinical trial data for higher-risk or novel claims.

The class determines not just what evidence you submit, but how long you’ll wait. Class I attestation-based applications typically get a 60-business-day review window. Class III submissions can run to 210 business days or more. Choosing the wrong class — or presenting Class II evidence for a claim that functionally requires Class III scrutiny — is one of the fastest ways to trigger a deficiency notice.

The Five Reasons NPN Applications Get Rejected Most Often

1. The claim and the evidence class don’t match.

This is the single most common structural error. A company submits a traditional use attestation for a claim that’s actually outcome-based — say, “reduces LDL cholesterol” or “clinically proven to improve immune response.” Traditional use claims must be supported by evidence of historical use in a recognized traditional medicine system. They cannot be supported by mechanism-of-action studies or clinical outcomes data, because those document a different kind of evidence entirely. Conversely, if you want to make a physiological claim with modern clinical language, you need Class II or Class III evidence to back it up. Health Canada’s screening reviewers are specifically trained to catch this misalignment.

2. Labelling doesn’t match the licensed ingredient monograph.

Health Canada’s Licensed Natural Health Products Database (LNHPD) includes hundreds of ingredient monographs specifying exactly how a medicinal ingredient must appear on a label — its proper name, acceptable synonyms, dosage ranges, cautions, and mandatory risk information. If your label uses a trade name or alternate botanical name that isn’t listed in the applicable monograph, that discrepancy needs to be resolved. We’ve seen applications delayed by three to four months over something as correctable as a Latin binomial listed in a non-preferred format, or a herbal extract ratio expressed differently from what the monograph permits.

3. Non-medicinal ingredients aren’t adequately characterized.

The NHPR requires that all non-medicinal ingredients be disclosed and identified by their proper or common name. For complex excipients — particularly those derived from natural sources — characterization data is sometimes incomplete. Reviewers look for confirmation that non-medicinal ingredients are appropriate for the target population (children, pregnant women, seniors) and don’t introduce safety concerns at the specified amounts. This is often an afterthought in dossier preparation, but it’s a formal requirement under Section 5.

4. The attestation form is missing or improperly completed.

For traditional use applications, the attestation is arguably the most critical document in the dossier. It must be signed by a qualified practitioner or researcher with demonstrable expertise in the relevant traditional medicine system — Traditional Chinese Medicine, Ayurveda, Western herbal medicine, and so on. If the attestor’s credentials aren’t clearly established, or if the attestation references a different product name than what appears in the application, the submission comes back. We’ve seen companies use attestors whose expertise is in a different traditional system than the one cited in the application — that’s an automatic deficiency, regardless of how thorough the rest of the dossier is.

5. Risk information is incomplete or internally inconsistent.

Every NPN application must include contraindications, known adverse reactions, drug-herb interaction warnings, and cautions relevant to the medicinal ingredients. If your evidence dossier references a known interaction — St. John’s Wort with SSRIs is the textbook example — but your proposed label doesn’t carry a corresponding warning, there’s an internal inconsistency that NNHPD will flag. Similarly, if a referenced ingredient monograph specifies a maximum recommended duration of use, your dosage recommendation must respect that limit. Reviewers cross-check these details against the monograph, and inconsistencies between the evidence section and the proposed label are among the most frequently cited deficiency reasons.

How to Structure a Submission That Passes Review

The highest-leverage step you can take before submitting is running your dossier against Health Canada’s own guidance documents — particularly the Pathway for Licensing Natural Health Products Using Traditional Evidence — and the relevant ingredient monographs in the LNHPD. Most deficiencies we encounter trace directly to misalignment with those two reference sources.

Beyond that, a few structural checkpoints make a real difference:

Run a claim-to-evidence cross-walk. Every claim on the label must be supported by a referenced evidence entry in the dossier. Every evidence entry cited must correspond to a claim or condition of use on the label. A claim without evidence and an evidence entry without a corresponding label claim are both deficiency triggers.

Lock your ingredient names before drafting. Determine the proper names under the NHPR Schedule 1 before any label copy is written. Using a name that is recognized only as a synonym, rather than the primary proper name, creates inconsistencies that ripple through the entire dossier — product name, evidence table, label, and attestation.

Get an independent pre-submission review. Health Canada does offer a Pre-Submission Meeting process for novel or particularly complex products, but it’s rarely used for standard NHP submissions. At minimum, someone who hasn’t been involved in drafting the dossier should read it from a reviewer’s perspective before submission. Regulatory tunnel vision is real — when you’ve been inside a dossier for months, it’s easy to stop seeing what’s missing.

Understand how the screening clock works. Health Canada screens submissions for administrative completeness before the substantive review period begins. A screening deficiency stops the clock entirely and returns the file to you. Every round of screening deficiencies adds weeks — sometimes months — to your timeline. Front-loading the quality of your submission is almost always faster than fixing deficiencies after the fact.

A Note on DIN-HM Versus NPN

One pathway mistake worth flagging separately: if your product is homeopathic — meaning it relies on potentiation and dilution — it requires a Drug Identification Number for Homeopathic Medicines (DIN-HM), not an NPN. The two pathways operate under fundamentally different evidence frameworks. Submitting a homeopathic preparation through the NPN pathway creates a structural mismatch that will result in rejection regardless of how strong the homeopathic evidence is, because that evidence simply isn’t evaluated under the NPN framework.

The distinction matters practically because DIN-HM submissions accept homeopathic evidence forms — provings, classical materia medica references, repertories — that would be inadmissible as NHP evidence. If your product contains both traditional medicinal ingredients and homeopathic components, the regulatory pathway becomes product-specific and is worth clarifying through a formal regulatory consultation before you invest in the dossier.

What a Realistic NPN Approval Timeline Looks Like

For a well-prepared Class I traditional use application — complete attestation, label aligned with the applicable monograph, consistent risk information — a realistic timeline from submission to approval is 3 to 4 months, assuming no screening deficiencies.

Class II applications targeting a specific physiological outcome typically run 6 to 9 months. Class III submissions with clinical data routinely reach 12 to 18 months, and sometimes longer if the NNHPD requests additional information during the scientific review stage.

These are practical timelines, not statutory deadlines. Health Canada does not guarantee review periods, and submission volume can create backlogs — particularly during periods of regulatory update or policy transition. If your product launch date is fixed, that date should drive your submission timing, not the other way around.

The Most Preventable Problem in NPN Submissions

Natural health products regulation in Canada is specific, reference-document-driven, and unforgiving of internal inconsistencies. The most effective way to prevent rejection isn’t to submit more evidence — it’s to ensure the evidence you do submit is precisely aligned with the claim you’re making, the class you’re applying under, and the ingredient standards Health Canada has already published.

Run your next NPN dossier against those reference documents before it goes in. It’s considerably cheaper to find the gaps internally than to discover them six months later in a Notice of Deficiency.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance — Contact us

Related from our network

• Supplement and NHP Testing for the North American Market — Qalitex Laboratories provides ISO 17025-accredited testing for natural health products sold in Canada and the US, including potency, heavy metals, and microbial analysis.
• Entering the European Market with a Natural Health Product — Care Europe covers EU-side regulatory requirements for botanical and NHP products, including EFSA health claim submissions and EU cosmetics notification.